Insider · CIK 0001774690

Leggett Thomas

Reports to the SEC for 4 companies · BEDFORD, MA

sec.gov

Transactions

Companies

Filings

CIK

0001774690

Forms 4 and 5

Insider transactions

30 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−37 sh	$32.85	−$1,215.45	10,172
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−2,173 sh	$31.28	−$68K	10,381
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−172 sh	$31.79	−$5,467.674	10,209
2026-03-17	STOKStoke Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,274 sh	$32.74	−$41.7K	13,476
2026-03-17	STOKStoke Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−922 sh	$33.38	−$30.8K	12,554
2026-03-15	STOKStoke Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+14.8K sh	—	—	14,750
2026-03-15	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−14.8K sh	—	—	44,250
2026-02-17	STOKStoke Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+60K sh	—	—	60,000
2026-02-17	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+40K sh	—	—	40,000
2025-03-20	STOKStoke Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+89K sh	—	—	89,000
2025-03-20	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Financial Officer	AAward	+59K sh	—	—	59,000
2024-05-15	STOKStoke Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+396K sh	—	—	396,200
2021-02-17	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+75K sh	—	—	75,000
2021-01-08	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$10.86	+$32.6K	3,000
2021-01-08	BDTXBlack Diamond Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$33.94	−$102K	0
2021-01-08	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	218,171
2020-12-08	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	221,171
2020-12-08	BDTXBlack Diamond Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,941 sh	$34.05	−$66.1K	0
2020-12-08	BDTXBlack Diamond Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−1,059 sh	$33.27	−$35.2K	1,941
2020-12-08	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$10.86	+$32.6K	3,000
2020-11-09	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	224,171
2020-11-09	BDTXBlack Diamond Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$32.96	−$98.9K	0
2020-11-09	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$10.86	+$32.6K	3,000
2020-10-08	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$10.86	+$32.6K	3,000
2020-10-08	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	227,171
2020-10-08	BDTXBlack Diamond Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$33.53	−$101K	0
2020-09-14	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	−3,000 sh	—	—	230,171
2020-09-14	BDTXBlack Diamond Therapeutics, Inc.S Sale	Chief Financial Officer	SSale	−3,000 sh	$31.00	−$93K	0
2020-09-14	BDTXBlack Diamond Therapeutics, Inc.M Exercise/Conversion	Chief Financial Officer	MExercise/Conversion	+3,000 sh	$10.86	+$32.6K	3,000
2020-01-29	BDTXBlack Diamond Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Chief Financial Officer	AAward	+55.5K sh	—	—	55,540

Recent filings

Accepted (ET)
Mar 194
Leggett Thomas0001774690-26-000006
SEC(opens sec.gov)
Mar 174
Leggett Thomas0001774690-26-000004
SEC(opens sec.gov)
Feb 194
Leggett Thomas0001774690-26-000002
SEC(opens sec.gov)
Mar 204
Leggett Thomas0001415889-25-008713
SEC(opens sec.gov)
May 174
Leggett Thomas0001415889-24-013477
SEC(opens sec.gov)
Feb 194
Leggett Thomas0000899243-21-007433
SEC(opens sec.gov)
Jan 114
Leggett Thomas0000899243-21-001378
SEC(opens sec.gov)
Dec 104
Leggett Thomas0000899243-20-033341
SEC(opens sec.gov)

Companies

Address

C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE

BEDFORD, MA, 01730